ZOMETA® Case Study of a Renal Cell Carcinoma Patient With a Poor Prognosis

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study - Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

How would you address Carlo's bone health?

Carlo's physician is concerned about the metastases to his vertebrae and would like to add ZOMETA^® to his therapy
Carlo believes his prognosis is poor and is asking whether it is worth it to come in for IV therapy in addition to oral sunitinib

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.